DM

Monday, June 17, 2013

Inostics' Blood-Based Mutation Testing Receives CLIA Certification

Main Category: Cancer / Oncology
Also Included In: Regulatory Affairs / Drug Approvals;??Blood / Hematology
Article Date: 04 Jun 2013 - 2:00 PDT Current ratings for:
Inostics' Blood-Based Mutation Testing Receives CLIA Certification
not yet ratednot yet rated
Inostics, a molecular diagnostics company that provides blood-based mutation testing, received CLIA (Clinical Laboratory Improvement Amendments) licensure for its clinical laboratory located in Baltimore, MD. This marks a critical milestone for the clinical adoption of this non-invasive molecular approach for the analysis of tumor biomarkers.

"Due to the non-invasiveness and real-time reflection of tumor genetics, the OncoBEAM blood test represents a valuable tool to complement clinical decision making. We are extremely excited to be able to bring this solution to cancer patients as OncoBEAM tests offer a significant enhancement to clinical care over traditional tissue-based molecular testing," Dr. Frank Diehl, CSO of Inostics, said.

The OncoBEAM blood test is based on BEAMing technology which combines emulsion based digital PCR with flow cytometry. This technology enables the molecular analysis of tumor DNA shed from primary and metastatic tumors, found circulating in the blood of patients.

Due to its non-invasiveness, OncoBEAM blood tests introduce new possibilities for the management of various cancers like skin, colorectal, breast, and lung cancer. Now a simple blood draw can support clinical decision making in the context of therapy selection, assessment of drug response, resistance and recurrence monitoring, and detection of minimal residual disease (MRD).

Article adapted by Medical News Today from original press release. Source: Source: Inostics
Visit our cancer / oncology section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Inostics. "Inostics' Blood-Based Mutation Testing Receives CLIA Certification." Medical News Today. MediLexicon, Intl., 4 Jun. 2013. Web.
5 Jun. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Inostics' Blood-Based Mutation Testing Receives CLIA Certification'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

No comments:

Post a Comment